Description

Aspadol 100 mg (Tapentadol Hydrochloride) Tablets

Aspadol 100 mg is an oral, centrally acting analgesic formulation containing tapentadol hydrochloride. It delivers dual-mechanism pain relief via two synergistic modes of action: moderate-affinity agonism at the $\mu$-opioid receptor ($\text{MOR}$) and direct inhibition of norepinephrine reuptake ($\text{NRI}$). Unlike prodrug opioids, tapentadol is an active parent compound with minimal relying metabolic activation and negligible serotonergic activity, providing broad coverage across both nociceptive and neuropathic pain pathways.

Product Overview

Primary Indications

Aspadol 100 mg is prescribed under licensed clinical supervision for:

• Moderate to Severe Acute Pain: Short-term relief of acute postsurgical pain, orthopaedic injury, severe dental trauma, or acute musculoskeletal pain where non-opioid analgesics are inadequate or contraindicated.

• Neuropathic and Mixed Pain States: Pain syndromes exhibiting both somatic and neuropathic components (e.g., painful diabetic peripheral neuropathy or severe radiculopathy) that respond to norepinephrine reuptake inhibition paired with $\mu$-opioid receptor activation.

Key Information & Precautions

• Dosage & Daily Maximums: Dosing must be strictly tailored by a healthcare provider. For immediate-release formulations, the standard ceiling dose is generally 500 mg on day 1 (including initial and titration doses) and up to 600 mg daily on subsequent days, administered in divided intervals (every 4 to 6 hours as prescribed).

• Boxed Warning — Addiction, Abuse, and Misuse: Tapentadol is a Schedule II controlled substance carrying high potential for opioid addiction, abuse, diversion, and misuse, which can lead to overdose and death. Therapy should be maintained at the lowest effective dose for the shortest duration necessary.

• Life-Threatening Respiratory Depression: Serious, potentially fatal respiratory depression can occur, particularly during therapy initiation or following dose escalations. Carbon dioxide retention secondary to hypoventilation can further increase intracranial pressure.

• Boxed Warning — Concomitant CNS Depressants: Co-administration with benzodiazepines, other sedative-hypnotics, alcohol, or illicit depressants significantly elevates the risk of profound sedation, respiratory arrest, coma, and fatality.

• Minimal CYP450 Interaction Burden: Because tapentadol undergoes extensive direct hepatic glucuronidation (phase-II metabolism) and minimal CYP450-mediated clearance, it carries a substantially lower risk of metabolic drug-drug interactions compared to tramadol, oxycodone, or hydrocodone, and does not depend on CYP2D6 genetic polymorphisms for efficacy.

• Seizure and Neuroexcitation Risk: Tapentadol can lower the seizure threshold. It should be used with extreme caution in patients with a history of epilepsy or head injury, or when co-administered with other seizure-potentiating drugs.

• Serotonin Syndrome & MAOI Precautions: While tapentadol has negligible affinity for serotonin reuptake compared to tramadol, concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI cessation is contraindicated due to additive adrenergic and monoaminergic toxicity. Caution is warranted when combined with other serotonergic agents.

• Physical Dependence & Tapering: Extended therapy leads to physical dependence. Abrupt cessation will precipitate typical opioid withdrawal symptoms (rhinorrhea, lacrimation, severe body aches, diaphoresis, insomnia, anxiety). Discontinuation requires a gradual, physician-directed dose taper.

• Psychomotor Impairment: Tapentadol causes somnolence, dizziness, and impaired cognitive response. Operating motor vehicles or complex machinery is contraindicated until patient stabilization is established.